drugset / Trial / NCT04280965

Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury

NCT04280965

RandomizedParallel-groupOpen-labelTreatment

Summary

A pilot study to evaluate feasibility for a full-scale merit application. Specifically, for veterans considering prolonged exposure (PE) therapy, following the model established by Foa et al, we need to establish safety, and feasibility of quetiapine compared to treatment as usual (TAU) which employs multiple medications commonly used for PTSD in the VA system.

Timeline

Start
2019-02-01
Primary completion
2022-04-29
Completion
2022-10-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 400 mg